Sheila Zipfel

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®

James G. Taylor, Sheila Zipfel, Kyla Ramey et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 83 citations

Molecular Virology, Viral Hepatitis, Immunology +6

Discovery of <i>S</i>-[5-Amino-1-(4-fluorophenyl)-1<i>H</i>-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase

David Goldstein, Tom Alfredson, J. A. Bertrand et al. · Journal of Medicinal Chemistry · 2006 · 64 citations · Full text

Identification of orally-bioavailable antagonists of the TRPV4 ion-channel

Zhi‐Liang Wei, Margaret Nguyen, Donogh J. R. O’Mahony et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 42 citations · Full text

Molecular Pharmacology, Medicine, Antiviral Drug Development +3

Advances in cathepsin S inhibitor design.

John O. Link, Sheila Zipfel · PubMed · 2006 · 35 citations

Immunology, Antigen Processing, Immunotherapy +18

P0899 : Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857

James G. Taylor, T.C. Appleby, Ona Barauskas et al. · Journal of Hepatology · 2015 · 31 citations

Molecular Virology, Medicine, Pathogenesis +8